Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
10/2003
10/22/2003CN1449760A Composition of danazol semisolid skeleton preparation
10/22/2003CN1125082C Human chemokine beta-8 chemokine beta-1 and macrophage inflammatory protein-4
10/22/2003CN1125049C New crystal modification N of torasemide
10/22/2003CN1124858C Medicine for treating blood vessel embolism and its preparing process
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635657 Pyridine derivatives; anticoagulants
10/21/2003US6635651 Inhibitors of thrombin induced platelet aggregation
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635638 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/21/2003US6635637 Cyclic oxyguanidine protease inhibitors
10/21/2003CA2156825C Inhibition of intimal hyperplasia using antibodies to pdgf receptors
10/21/2003CA2072649C Methods and materials for expression of human plasminogen variant
10/16/2003WO2003085089A2 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
10/16/2003WO2003084966A1 Oxazolidinone derivatives
10/16/2003WO2003084963A1 Non-steroidal progesterone receptor modulators
10/16/2003WO2003084955A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084929A1 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
10/16/2003WO2003084922A1 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
10/16/2003WO2003084545A1 Drug containing riboflavin compound
10/16/2003WO2003084533A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003WO2003084528A1 A method for reversing permeability modifications caused by acute peritonitis
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084525A1 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003057729A3 Mammal prolactin variants
10/16/2003WO2003039439A3 Deuterated pyrazolopyrimidinones and drugs containing said compounds
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003022997A3 Human tissue urokinase type plasminogen activator formulation
10/16/2003WO2003014391A3 Method for the detection of a polymorphism in cpb2
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2002084298A3 Medicaments which are modulators of hm74 and/or hm74a activity
10/16/2003WO2002064065A3 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195251 For therapy of psychiatric, pain and other disorders
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195236 Heterocyclic imines such as 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine, used for prophylaxis of vitamin B6 deficiency, cardiovascular disorders or melanomas
10/16/2003US20030195231 Heterocyclic sulfur compounds and/or prodrugs administered for prophylaxis of thrombocytopenia, anemia or blood disorders
10/16/2003US20030195230 Substituted amine derivatives and methods of use
10/16/2003US20030195223 Antithrombotic agents
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195214 Cancer treatment
10/16/2003US20030195212 An amide derivatives for treating obesity, anorexia, inflammation, mental diseases associated with the melanocyte stimulating hormones
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195210 An enzyme inhibitors of cyclic guanosine 3',5'-monophophate-metabolizing phosphodiesterases; treating cardiovascular disorders, brian disorders, Alzheimer's disease, urogenital or sexual disorders
10/16/2003US20030195203 Heterocyclic derivatives
10/16/2003US20030195193 Useful as activated blood coagulation factor X inhibitor; useful as an anticoagulant or an agent for prophylaxis and therapy of diseases caused by thrombus or embolus
10/16/2003US20030195188 Pyridine and quinoline derivatives
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195160 Sodium channel blockers
10/16/2003US20030195154 Comprises mimetics of erythropoietin, thrombopoietin, and glucagon-like peptide conjugated to polymer
10/16/2003US20030194802 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194413 Methods and compositions employing red rice fermentation products
10/16/2003US20030194404 Gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules; especially for treating asthma and other respiratory system disorders
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194389 Occlusive composition
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481817A1 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
10/16/2003CA2481026A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003CA2480697A1 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2479927A1 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
10/16/2003CA2478340A1 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
10/16/2003CA2462708A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/15/2003EP1352956A1 Inhibition of DNA methyltransferase
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352655A1 Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
10/15/2003EP1352063A2 Receptor nucleic acids and polypeptides
10/15/2003EP1351986A2 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
10/15/2003EP1351985A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351953A1 Quinoline derivatives as nk-3 antagonists
10/15/2003EP1351938A1 Phenyl derivatives
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351916A2 Ether compounds and compositions for cholesterol management and related uses
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351706A2 Method for treating hemophilia b
10/15/2003EP1351705A1 Compositions for treatement of hemorrhaging with activated factor viia in combination with fibrinogen
10/15/2003EP1351686A2 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/15/2003EP1351681A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
10/15/2003EP1351672A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
10/15/2003EP1351668A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
1 ... 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 ... 671